Cargando…

Cancer Response to Therapy-Induced Senescence: A Matter of Dose and Timing

SIMPLE SUMMARY: Cellular senescence consists of a permanent block of cell proliferation in the presence of an active metabolism. It is a physiological process occurring when cells exhaust their proliferative potential, as signaled by critical telomere erosion. Additionally, cell senescence might be...

Descripción completa

Detalles Bibliográficos
Autores principales: Mongiardi, Maria Patrizia, Pellegrini, Manuela, Pallini, Roberto, Levi, Andrea, Falchetti, Maria Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7865402/
https://www.ncbi.nlm.nih.gov/pubmed/33513872
http://dx.doi.org/10.3390/cancers13030484
_version_ 1783647837805871104
author Mongiardi, Maria Patrizia
Pellegrini, Manuela
Pallini, Roberto
Levi, Andrea
Falchetti, Maria Laura
author_facet Mongiardi, Maria Patrizia
Pellegrini, Manuela
Pallini, Roberto
Levi, Andrea
Falchetti, Maria Laura
author_sort Mongiardi, Maria Patrizia
collection PubMed
description SIMPLE SUMMARY: Cellular senescence consists of a permanent block of cell proliferation in the presence of an active metabolism. It is a physiological process occurring when cells exhaust their proliferative potential, as signaled by critical telomere erosion. Additionally, cell senescence might be triggered as a response to different stresses: DNA damage, oxidative stress and oncogenic activation. Whatever the senescence-inducing stress is, a peculiarity of senescent cells is the production of an altered secretome, the Senescence-Associated Secretory Phenotype (SASP), which profoundly affects the cellular microenvironment. Cancer therapy, either ionizing radiations or chemotherapy, induces cellular senescence, the so-called therapy-induced senescence (TIS). The issue of whether TIS is a pro- or anti-tumorigenic process is a current and open question. ABSTRACT: Cellular senescence participates to fundamental processes like tissue remodeling in embryo development, wound healing and inhibition of preneoplastic cell growth. Most senescent cells display common hallmarks, among which the most characteristic is a permanent (or long lasting) arrest of cell division. However, upon senescence, different cell types acquire distinct phenotypes, which also depend on the specific inducing stimuli. Senescent cells are metabolically active and secrete a collection of growth factors, cytokines, proteases, and matrix-remodeling proteins collectively defined as senescence-associated secretory phenotype, SASP. Through SASP, senescent cells modify their microenvironment and engage in a dynamic dialog with neighbor cells. Senescence of neoplastic cells, at least temporarily, reduces tumor expansion, but SASP of senescent cancer cells as well as SASP of senescent stromal cells in the tumor microenvironment may promote the growth of more aggressive cancer subclones. Here, we will review recent data on the mechanisms and the consequences of cancer-therapy induced senescence, enlightening the potentiality and the risk of senescence inducing treatments.
format Online
Article
Text
id pubmed-7865402
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78654022021-02-07 Cancer Response to Therapy-Induced Senescence: A Matter of Dose and Timing Mongiardi, Maria Patrizia Pellegrini, Manuela Pallini, Roberto Levi, Andrea Falchetti, Maria Laura Cancers (Basel) Review SIMPLE SUMMARY: Cellular senescence consists of a permanent block of cell proliferation in the presence of an active metabolism. It is a physiological process occurring when cells exhaust their proliferative potential, as signaled by critical telomere erosion. Additionally, cell senescence might be triggered as a response to different stresses: DNA damage, oxidative stress and oncogenic activation. Whatever the senescence-inducing stress is, a peculiarity of senescent cells is the production of an altered secretome, the Senescence-Associated Secretory Phenotype (SASP), which profoundly affects the cellular microenvironment. Cancer therapy, either ionizing radiations or chemotherapy, induces cellular senescence, the so-called therapy-induced senescence (TIS). The issue of whether TIS is a pro- or anti-tumorigenic process is a current and open question. ABSTRACT: Cellular senescence participates to fundamental processes like tissue remodeling in embryo development, wound healing and inhibition of preneoplastic cell growth. Most senescent cells display common hallmarks, among which the most characteristic is a permanent (or long lasting) arrest of cell division. However, upon senescence, different cell types acquire distinct phenotypes, which also depend on the specific inducing stimuli. Senescent cells are metabolically active and secrete a collection of growth factors, cytokines, proteases, and matrix-remodeling proteins collectively defined as senescence-associated secretory phenotype, SASP. Through SASP, senescent cells modify their microenvironment and engage in a dynamic dialog with neighbor cells. Senescence of neoplastic cells, at least temporarily, reduces tumor expansion, but SASP of senescent cancer cells as well as SASP of senescent stromal cells in the tumor microenvironment may promote the growth of more aggressive cancer subclones. Here, we will review recent data on the mechanisms and the consequences of cancer-therapy induced senescence, enlightening the potentiality and the risk of senescence inducing treatments. MDPI 2021-01-27 /pmc/articles/PMC7865402/ /pubmed/33513872 http://dx.doi.org/10.3390/cancers13030484 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Mongiardi, Maria Patrizia
Pellegrini, Manuela
Pallini, Roberto
Levi, Andrea
Falchetti, Maria Laura
Cancer Response to Therapy-Induced Senescence: A Matter of Dose and Timing
title Cancer Response to Therapy-Induced Senescence: A Matter of Dose and Timing
title_full Cancer Response to Therapy-Induced Senescence: A Matter of Dose and Timing
title_fullStr Cancer Response to Therapy-Induced Senescence: A Matter of Dose and Timing
title_full_unstemmed Cancer Response to Therapy-Induced Senescence: A Matter of Dose and Timing
title_short Cancer Response to Therapy-Induced Senescence: A Matter of Dose and Timing
title_sort cancer response to therapy-induced senescence: a matter of dose and timing
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7865402/
https://www.ncbi.nlm.nih.gov/pubmed/33513872
http://dx.doi.org/10.3390/cancers13030484
work_keys_str_mv AT mongiardimariapatrizia cancerresponsetotherapyinducedsenescenceamatterofdoseandtiming
AT pellegrinimanuela cancerresponsetotherapyinducedsenescenceamatterofdoseandtiming
AT palliniroberto cancerresponsetotherapyinducedsenescenceamatterofdoseandtiming
AT leviandrea cancerresponsetotherapyinducedsenescenceamatterofdoseandtiming
AT falchettimarialaura cancerresponsetotherapyinducedsenescenceamatterofdoseandtiming